A method of treatment of infection in a subject comprising administering to the subject a copolymer comprising an acrolein derived segment or a polyacrolein oligomer segment and a polyalkylene glycol oligomer segment, the copolymer having a molecular weight of no more than 1500 Daltons.

A fluoropolymer having fluoropolyether linkages, at least two ester linkages, and hydrolyzable functional groups is represented by chemical structure (I):

##STR00001##

With respect to chemical structure (I), m is a number from 1 to 4 and n is a number from 10 to 60, each R.sup.1 is independently fluorine or CF.sub.3, R.sup.2 is an alkylene group, R.sup.3 is an alkylene group in which one or more hydrogens of the alkylene group are optionally substituted with fluorine, R.sup.4 is an alkyl group in which one or more hydrogens of the alkyl group are substituted with fluorine, R.sup.5 is an alkylene group in which at least one hydrogen of the alkylene group is substituted with a group comprising CF.sub.3, CF.sub.2H, or a hydrolyzable silyl group, and Z is a group represented by chemical structure (II),

##STR00002##

Methods of preparing the fluoropolymer and coating compositions containing the fluoropolymer are also included.

The present invention provides, among other things, compounds that include a water-soluble and non-peptidic polymer as well as a maleimidyl group. The compounds are useful as, among other things, polymeric reagents.

A compound comprising a cyclodextrin and a monoalkoxy polyethylene glycol linked thereto through an ether bond (a pegylated cyclodextrin) is disclosed, as are drug delivery vehicles and pharmaceutical formulations including the same, and methods for making the compound and the drug delivery vehicle and for delivering the drug to a patient in need thereof. The method of making includes the steps of creating either a tosylated monoalkoxy polyethylene glycol or a tosylated cyclodextrin, and either reacting the tosylated monoalkoxy polyethylene glycol with a deprotonated cyclodextrin, or reacting the tosylated cyclodextrin with a deprotonated monoalkoxy polyethylene glycol. The present pegylated cyclodextrin readily forms an inclusion compound with certain drugs to protect the drug against adverse interactions with mucin (e.g., in a mucus membrane).

Vinyl-functional alcohols are silylated by reaction with a hydrolysable silyl hydride compound. The starting alcohol is heated and then combined with the silyl hydride and catalyst and allowed to heat exothermically. Cooling is applied when the conversion of vinyl groups is between 90-99%. In some embodiments, specified amounts of water are present. The cooling regimen and control of water content reduces certain side reactions, leading to greater yields to desired product.

Provided are a polyol glyceryl ether, and a multi-armed polyethylene glycol and the multi-armed polyethylene glycol active derivative prepared using the same. The multi-armed polyethylene glycol is formed by polymerizing ethylene oxide with the polyol glyceryl ether as an initiator, and has the structure of general formula II, wherein B is a polyol group, n is an integer between 3 and 22, PEG is the same or not the same (OCH.sub.2CH.sub.2).sub.m, and the average value of m is an integer between 3 and 250. The multi-armed polyethylene glycol has a relatively low poly-dispersity and a relatively high determined molecular weight. Also provided is a conjugate of the multi-armed polyethylene glycol active derivative and pharmaceutical molecules, a pharmaceutical composition comprising the conjugate, and a gel formed by the multi-armed polyethylene glycol active derivative. The gel can be used to prepare a sustained-release drug for prolonging the time of the drug action.

The present invention provides, among other things, compounds that include a water-soluble and non-peptidic polymer as well as a maleimidyl group. The compounds are useful as, among other things, polymeric reagents.

A compound having the formula: ##STR00001## wherein n, y, R.sub.1 and R.sub.2 are defined herein, and others, methods of making of and using, and compositions made thereby which have an antimicrobial resistance effect are described.

(Per)fluoropolyether polymers comprising a (per)fluoropolyether chain having two ends, wherein one or both ends comprise one or more zwitterionic groups at one or both polymer ends, methods for their manufacture and uses thereof are herein disclosed. The polymers can be used in particular for protecting materials in contact with biological fluids or fluids containing biological material from contamination by organic compounds therein contained.

There is provided a composition for gel electrolyte that can impart excellent power characteristics and a high capacity retention ratio to an electrochemical capacitor. The composition for gel electrolyte comprises an electrolyte salt and a polyether copolymer having an ethylene oxide unit, wherein the composition for gel electrolyte has a water content of 50 ppm or less.